###begin article-title 0
###xml 34 39 <span type="species:ncbi:9606">Women</span>
Increased sFlt-1 to PlGF Ratio in Women Who Subsequently Develop Preeclampsia
###end article-title 0
###begin p 1
###xml 575 576 575 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 633 634 633 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 713 714 713 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 824 825 824 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 950 951 950 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1159 1160 1159 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 200 205 <span type="species:ncbi:9606">women</span>
###xml 367 372 <span type="species:ncbi:9606">women</span>
###xml 544 549 <span type="species:ncbi:9606">women</span>
###xml 752 757 <span type="species:ncbi:9606">women</span>
###xml 919 924 <span type="species:ncbi:9606">women</span>
The purpose of this study was to determine whether the levels of soluble fms-like tyrosine kinase-1 (sFlt-1) and placenta growth factor (PlGF) are altered during the second trimester in the plasma of women who subsequently develop preeclampsia. We performed a case-control study to compare the levels of sFlt-1 and PlGF in the preeclamptic (n=46) and normal pregnant women (n=100). The maternal plasma levels of sFlt-1 and PlGF were measured by enzyme-linked immunosorbent assay. The sFlt-1 levels were significantly higher in the preeclamptic women than in normal controls (p<0.001), while the PlGF levels were significantly lower (p<0.001). In normal controls, sFlt-1 levels were positively correlated (r=0.27, p=0.008), whereas, in the preeclamptic women, those were negatively correlated with the PlGF levels (r=-0.423, p=0.005). Furthermore, the log[sFlt-1/PlGF] ratio was significantly higher in the preeclamptic women than in normal controls (p<0.001). The receiver operating characteristic curve revealed a specificity of 78% with a diagnostic sensitivity of 80.4%; the optimal cut-off value of the log[sFlt-1/PlGF] ratio was 1.4 (95% CI 0.756-0.910, p<0.001). Preeclampsia showed a strong association with increased levels of sFlt-1 and decreased levels of PlGF in the second trimester maternal plasma. Accordingly, the sFlt-1/PlGF ratio may provide early prediction of subsequent development of preeclampsia.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
Preeclampsia, a pregnancy-specific syndrome affecting about 5% to 10% of pregnancies, is characterized by the presence of hypertension and proteinuria. This syndrome is one of the leading causes of maternal and fetal morbidity and mortality worldwide and occurs only in the presence of a placenta and remits dramatically after the placenta has been delivered. Although the exact pathogenesis of preeclampsia remains unclear, it has been suggested that endothelial dysfunction may play a central role in the development of preeclampsia. Impaired trophoblastic invasion of the maternal placental bed is considered to be the initial event of endothelial dysfunction in preeclampsia. Consequently, reduction of uteroplacental blood perfusion by shallow implantation results in local placental hypoxia. A hypoxic/ischemic placenta may then release placental factors into the maternal circulation eventually causing endothelial dysfunction, which leads to the main clinical symptoms of preeclampsia (including hypertension and proteinuria).
###end p 3
###begin p 4
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 586 587 586 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 589 590 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 736 737 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 739 740 739 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 865 866 865 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 868 869 868 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1019 1020 1019 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1283 1284 1283 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 820 825 <span type="species:ncbi:9606">women</span>
###xml 929 933 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 1186 1191 <span type="species:ncbi:9606">women</span>
###xml 1235 1240 <span type="species:ncbi:9606">women</span>
A role of the balance between soluble fms-like tyrosine kinase (sFlt-1) and placental growth factor (PlGF) in the pathogenesis of preeclampsia has been proposed by several investigators (1-4). sFlt-1 is a secreted splice variant of Flt-1 that antagonizes vascular endothelial growth factor (VEGF) and PlGF by binding, and prevents their interaction with endothelial receptors on the cell surface (5). PlGF is a secreted dimeric glycoprotein that possesses potent angiogenic and mitogenic activities capable of inducing the proliferation, migration, and activation of endothelial cells (6, 7). It has been recently shown that increased sFlt-1 occurs approximately five to six weeks before the onset of clinical symptoms of preeclampsia (1, 2), whereas decreased PlGF levels are observed prior to 20 weeks of gestation in women who subsequently develop preeclampsia (3, 4). Moreover, administration of exogenous sFlt-1 to pregnant rats leads to reduced PlGF, hypertension, proteinuria, and glomerular endothelial injury (8). Therefore, the pathogenesis of preeclampsia may involve an imbalance of angiogenic factors, and the measurement of sFlt-1 in combination with PlGF may distinguish women who subsequently develop preeclampsia from women who remain normotensive during pregnancy (8).
###end p 4
###begin p 5
###xml 108 113 <span type="species:ncbi:9606">women</span>
In this study we investigated whether the second trimester plasma levels of sFlt-1 and PlGF were altered in women who subsequently developed preeclampsia.
###end p 5
###begin title 6
MATERIALS AND METHODS
###end title 6
###begin title 7
Subjects
###end title 7
###begin p 8
###xml 168 173 <span type="species:ncbi:9606">women</span>
###xml 282 287 <span type="species:ncbi:9606">women</span>
###xml 850 855 <span type="species:ncbi:9606">women</span>
###xml 1257 1262 <span type="species:ncbi:9606">women</span>
Subjects were recruited from the Obstetrics and Gynecology Department at Cheil General Hospital between Octerber 2001 and December 2003. The study subjects included 46 women who subsequently developed preeclampsia (17 with mild preecalmpsia and 29 with severe preeclampsia) and 100 women with normal pregnancies who were matched for race, maternal age, and gestational age at the time of blood sampling. Preeclampsia was defined as hypertension (systolic blood pressure >/=140 mmHg and diastolic blood pressure >/=90 mmHg after 20 weeks gestation) and proteinuria (>/=300 mg in a 24 hr urine collection or >/=1+ on dipstick testing). Exclusion criteria included major congenital anomalies, fetal chromosomal abnormalities, multiple pregnancies, chronic hypertension, diabetes mellitus, and renal disease. Control subjects were selected randomly from women who were normotensive and without proteinuria throughout pregnancy and who delivered a healthy neonate at term without significant medical or obstetric complications such as; chronic hypertension, diabetes, renal insufficiency, congenital anomalies or fetal demise. This study was approved by the Ethics Committee at Cheil General Hospital, and written informed consent was obtained from all enrolled women.
###end p 8
###begin title 9
Samples and immunoassay
###end title 9
###begin p 10
Maternal blood was obtained at 14 to 23 weeks of gestation and was collected into heparinized vacutainer tubes. Maternal plasma samples were isolated by 2,500 g centrifugation for 10 min. Aliquots of maternal plasma were stored at -70℃ until analysis. Levels of sFlt-1 and PlGF in maternal plasma were measured with a commercially available enzyme-linked immunosorbent assay (ELISA, R&D System, Minneapolis, MN, U.S.A.) according to the manufacture's instructions. All samples were examined in duplicate, and the mean values of individual samples were used for statistical analysis. The minimal detectable levels in the assays of sFlt-1 and PlGF were 5.0 and 7.0 pg/mL, respectively. The inter- and intra-assay coefficients of variation were 3.8% and 7.0% for sFlt-1 and 3.6% and 11.0% for PlGF, respectively.
###end p 10
###begin title 11
Statistical analysis
###end title 11
###begin p 12
###xml 305 306 303 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 981 982 979 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 628 633 <span type="species:ncbi:9606">women</span>
All data are presented as the median (range) and number (percentage). Data not normally distributed were analyzed by nonparametric tests. A comparison of continuous variables between the two groups was performed using the Student's t test or Mann-Whitney U test, and proportions were compared with the chi2 test or Fisher's exact test. Spearman's rank correlation was used to assess the relationship between the two variables. Receiver operating characteristic (ROC) analysis was performed to assess the best cut-off value and discriminating capacity of the log[sFlt-1/PlGF] ratios in the second trimester plasma for predicting women who subsequently developed preeclampsia. Sensitivity, specificity, and odds ratio (OR) with 95% confidence intervals (CI) were calculated in order to consider the predictive efficacy of the log[sFlt-1/PlGF] ratio. Statistical analysis was performed with the Statistical Package for Social Sciences version 10.0 (SPSS Inc., Chicago, IL, U.S.A.). A p value <0.05 was considered statistically significant.
###end p 12
###begin title 13
RESULTS
###end title 13
###begin p 14
###xml 66 73 66 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 228 233 <span type="species:ncbi:9606">women</span>
###xml 333 338 <span type="species:ncbi:9606">women</span>
###xml 467 472 <span type="species:ncbi:9606">women</span>
The clinical characteristics of the study population are shown in Table 1. There were no significant differences in maternal age, gestational age at blood sampling, or platelet count between the preeclamptic and normal pregnant women. As expected, systolic and diastolic blood pressures were significantly higher in the preeclamptic women than in normal controls. By contrast, nulliparity, gestational age at delivery, and birth weight were lower in the preeclamptic women than in the normal controls.
###end p 14
###begin p 15
###xml 177 178 177 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 187 194 187 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1A</xref>
###xml 369 370 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 379 386 379 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1B</xref>
###xml 389 395 389 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 607 608 607 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 723 724 723 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1018 1019 1018 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1028 1034 1028 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 1236 1237 1236 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1246 1252 1246 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 1411 1412 1411 1412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 76 81 <span type="species:ncbi:9606">women</span>
###xml 284 289 <span type="species:ncbi:9606">women</span>
###xml 502 507 <span type="species:ncbi:9606">women</span>
###xml 824 829 <span type="species:ncbi:9606">women</span>
###xml 930 935 <span type="species:ncbi:9606">women</span>
###xml 1255 1260 <span type="species:ncbi:9606">Women</span>
Maternal plasma sFlt-1 levels were significantly higher in the preeclamptic women than in normal controls (median 3,861, range 1,389-15,915 vs. median 2,353, range 1,071-6,898, p<0.001) (Fig. 1A). The levels of maternal plasma PlGF levels were significantly lower in the preeclamptic women than in normal controls (median 86, range 29-232 vs. median 146, range 68-380, p<0.001) (Fig. 1B). Fig. 2 presents the correlation between the plasma sFlt-1 and PlGF levels in the two groups. In the preeclamptic women, there was a significant negative correlation between the plasma sFlt-1 and PlGF levels (r=-0.423, p=0.005), whereas there was a significant positive correlation between these variables in normal controls (r=0.270, p=0.008). We also evaluated the ratio of log[sFlt-1/PlGF] in the maternal plasma of the preeclamptic women and normal controls. The plasma log[sFlt-1/PlGF] ratio was significantly higher in the preeclamptic women than in normal controls (median 1.6, range 1.0-2.9 vs. median 1.2, range 0.5-1.9, p<0.001) (Fig. 3). The maternal plasma log[sFlt-1/PlGF] ratio with the cut-off value of 1.4 provided the best combination with 80.4% sensitivity and 78% specificity (area under the curve [95% CI]: 0.833 [0.756-0.910], p<0.001) (Fig. 4). Women with the maternal plasma log[sFlt-1/PlGF] ratio of > 1.4 had an increased risk of subsequently developing preeclampsia (OR [95% CI]: 17.0 [7.3-39.5], p<0.001).
###end p 15
###begin title 16
DISCUSSION
###end title 16
###begin p 17
###xml 102 107 <span type="species:ncbi:9606">women</span>
###xml 176 181 <span type="species:ncbi:9606">women</span>
###xml 288 293 <span type="species:ncbi:9606">women</span>
###xml 411 416 <span type="species:ncbi:9606">women</span>
###xml 760 765 <span type="species:ncbi:9606">women</span>
We found a decreased level of PlGF and an increased level of sFlt-1 in the second trimester plasma of women who subsequently developed preeclampsia compared to normal pregnant women. Moreover, PlGF levels of the normal controls were positively correlated, while those of the preeclamptic women were negatively correlated with sFlt-1 levels. Our data also revealed that the sFlt-1/PlGF ratio in the preeclamptic women was significantly higher compared to normal controls. We speculated that preeclampsia may be secondary to endothelial dysfunction caused by the imbalance of circulating angiogenic factors of placental origin, such as sFlt-1 and PlGF. Further analysis will be required to clarify the regulation of angiogenic factors and their secretion in the women with preeclampsia as well as the role of angiogenic factors in the pathophysiology of preeclampsia.
###end p 17
###begin p 18
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 524 525 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 527 528 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 776 778 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 298 303 <span type="species:ncbi:9606">women</span>
###xml 693 698 <span type="species:ncbi:9606">women</span>
Our data regarding both sFlt-1 and PlGF levels are consistent with the previous studies of Chaiworapongsa et al. (9) and Koga et al. (10) who found elevated plasma/serum concentrations of sVEGFR-1 in patients with preeclampsia at the time of diagnosis. In addition, the placentas from preeclamptic women have been shown to produce higher concentrations of sFlt-1 in vitro compared to normal controls (11, 12). Excess placental sFlt-1 may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia (3, 8). Several studies have documented that beginning in the early second trimester, and as early as 10 to 11 weeks of gestation, the plasma/serum PlGF concentration in women who go on to develop preeclampsia is lower than in normotensive controls (13-16).
###end p 18
###begin p 19
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 642 643 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 822 823 822 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 1085 1087 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 369 377 <span type="species:ncbi:9606">patients</span>
###xml 538 543 <span type="species:ncbi:9606">women</span>
###xml 775 780 <span type="species:ncbi:9606">women</span>
###xml 886 891 <span type="species:ncbi:9606">women</span>
The results of current studies suggest that the identification of high concentrations of sFlt-1 combined with low concentrations of PlGF may be used to predict the development of preeclampsia several weeks in advance of clinical onset of symptoms (1, 3, 17). Levine et al. (1) reported that the increase of sFlt-1 corresponds to a decrease of free PlGF in the serum of patients with preeclampsia resulting in endothelial dysfunction. Their results revealed that preeclampsia is associated with increased sFlt-1 concentrations in pregnant women five weeks before clinical disease and also with decreased PlGF from 13 to 16 weeks of gestation (1). Furthermore, the combination of first-trimester maternal serum concentrations of sFlt-1 (high) and PlGF (low) clearly identifies women at high risk of subsequent preeclampsia (3). The combination of both serum PlGF and sFlt-1 distinguished women who subsequently developed preeclampsia from those who subsequently developed gestational hypertension, delivered SGA (small for gestational age) newborns or completed a normal-term pregnancy (17).
###end p 19
###begin p 20
###xml 101 102 101 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 678 680 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 253 258 <span type="species:ncbi:9606">women</span>
###xml 590 595 <span type="species:ncbi:9606">women</span>
Some investigators have suggested that the sFlt-1/PlGF ratio may be predictive of preeclampsia risk (1). In the present study, we evaluated the preeclampsia risk in relationship to the sFlt-1/PlGF ratio. In agreement with previous reports, preeclamptic women in our study had a higher sFlt-1/PlGF ratio compared to the normal controls. In addition, a recent study has demonstrated that severe preeclampsia is associated with increased urinary output of sFlt-1 and a decreased output of PlGF at the time of clinical manifestation (18). Therefore, rapid noninvasive screening of hypertensive women based on the Flt-1/PlGF ratio may be used to define the severity of preeclampsia (18). These findings suggest that alteration of sFlt-1 and PlGF levels may be important in the pathophysiology of preeclampsia.
###end p 20
###begin p 21
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 100 105 <span type="species:ncbi:9606">women</span>
###xml 814 819 <span type="species:ncbi:9606">women</span>
The mechanisms responsible for the alternation of maternal plasma sFlt-1 and PlGF concentrations in women with preeclampsia remain unknown. In vitro studies have shown that PlGF is decreased (19) and sFlt-1 is increased (20) in trophoblast cells under conditions of reduced oxygen tension. It appears that PlGF deficiency and sFlt-1 excess may result from placental hypoxia associated with incomplete remodeling of maternal spiral arteries. The incompletely remodeled arteries offer persistently high resistance to uterine artery blood flow, and they may be predisposed to vascular rupture in the placental bed, especially after the onset of hypertension (21, 22). However, there is still not enough evidence to support the notion that altered levels of these angiogenic factors in maternal plasma of preeclamptic women are the consequence or the cause of a placentation deficit. Furthermore, the specific role of sFlt-1 and PlGF in the physiologic and pathologic development of placentation requires further investigation.
###end p 21
###begin p 22
###xml 126 131 <span type="species:ncbi:9606">women</span>
###xml 204 209 <span type="species:ncbi:9606">women</span>
###xml 318 323 <span type="species:ncbi:9606">women</span>
###xml 392 397 <span type="species:ncbi:9606">women</span>
In summary, our results showed that sFlt-1 levels were increased and PlGF levels were decreased in second trimester plasma of women who subsequently developed preeclampsia compared to the normal pregnant women, and that a negative correlation existed between the circulating sFlt-1 and PlGF levels in the preeclamptic women. We also found that sFlt-1/PlGF ratios were significantly higher in women with preeclampsia than in normal controls. Although sFlt-1 and PlGF have been shown to be associated with preeclampsia and may be potential markers for the early prediction of preeclampsia before clinical manifestations are identified, further prospective, large-scale, longitudinal studies are essential to determine the usefulness of sFlt-1 and PlGF in predicting preeclampsia.
###end p 22
###begin p 23
###xml 38 57 38 57 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRF-2005-041-E00222</award-id>
###xml 65 90 65 90 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Korea Research Foundation</funding-source>
This study was supported by Grant No. KRF-2005-041-E00222 of the Korea Research Foundation.
###end p 23
###begin article-title 24
Circulating angiogenic factors and the risk of preeclampsia
###end article-title 24
###begin article-title 25
###xml 100 108 <span type="species:ncbi:9606">patients</span>
Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop
###end article-title 25
###begin article-title 26
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia
###end article-title 26
###begin article-title 27
Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies
###end article-title 27
###begin article-title 28
Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
###end article-title 28
###begin article-title 29
Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth
###end article-title 29
###begin article-title 30
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
###end article-title 30
###begin article-title 31
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia
###end article-title 31
###begin article-title 32
Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia
###end article-title 32
###begin article-title 33
###xml 90 95 <span type="species:ncbi:9606">women</span>
Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia
###end article-title 33
###begin article-title 34
###xml 71 76 <span type="species:ncbi:9606">human</span>
Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome
###end article-title 34
###begin article-title 35
Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies
###end article-title 35
###begin article-title 36
Decreased maternal serum placenta growth factor in early second trimester and preeclampsia
###end article-title 36
###begin article-title 37
###xml 49 54 <span type="species:ncbi:9606">women</span>
A longitudinal study of biochemical variables in women at risk of preeclampsia
###end article-title 37
###begin article-title 38
Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia
###end article-title 38
###begin article-title 39
###xml 86 91 <span type="species:ncbi:9606">women</span>
Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia
###end article-title 39
###begin article-title 40
Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies
###end article-title 40
###begin article-title 41
###xml 71 76 <span type="species:ncbi:9606">women</span>
Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia
###end article-title 41
###begin article-title 42
###xml 91 96 <span type="species:ncbi:9606">human</span>
Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast
###end article-title 42
###begin article-title 43
Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review
###end article-title 43
###begin article-title 44
Abruptio placentae. A "classic" dedicated to Elizabeth Ramsey
###end article-title 44
###begin article-title 45
Placental bed biopsies in placental abruption
###end article-title 45
###begin p 46
###xml 39 40 39 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 52 53 52 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 507 508 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 535 536 535 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 115 120 <span type="species:ncbi:9606">women</span>
Box plots indicating levels of sFlt-1 (A) and PlGF (B) in maternal plasma between normal controls and preeclamptic women. Boxes denote the interquartile range with the upper and lower horizontal edges representing the 75th and 25th percentiles, respectively. The central horizontal lines represent the medians. The vertical whiskers above and below the boxes represent the range of outlying data points up to 1.5 times the interquartile range, and the circles beyond the whiskers represent severe outliers. *Statistically significant, p<0.05.
###end p 46
###begin p 47
###xml 82 87 <span type="species:ncbi:9606">women</span>
###xml 195 200 <span type="species:ncbi:9606">women</span>
Correlation between sFlt-1 and PlGF levels in maternal plasma of the preeclamptic women (●) and normal controls (o). The solid and dashed lines indicate the regression lines for the preeclamptic women and normal controls, respectively.
###end p 47
###begin p 48
###xml 504 505 504 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 532 533 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 112 117 <span type="species:ncbi:9606">women</span>
Box plots indicating ratios of the log[sFlt-1/PlGF] in maternal plasma between normal controls and preeclamptic women. Boxes denote the interquartile range with the upper and lower horizontal edges representing the 75th and 25th percentiles, respectively. The central horizontal lines represent the medians. The vertical whiskers above and below the boxes represent the range of outlying data points up to 1.5 times the interquartile range, and the circles beyond the whiskers represent severe outliers. *Statistically significant, p<0.05.
###end p 48
###begin p 49
Receiver operating characteristic curve (ROC) showing the ability of the maternal plasma log[sFlt-1/PlGF] to differentiate preeclampsia from normal pregnancies. AUC, area under the curve.
###end p 49
###begin p 50
Clinical characteristics of the study population
###end p 50
###begin p 51
Values are expressed as median (range) or number (%).
###end p 51
###begin p 52
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 28 29 28 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
*Statistically significant, p<0.05.
###end p 52

